



AMERICAN GENE TECHNOLOGIES TO PRESENT AT 2018 CELL & GENE MEETING ON THE MESA

ROCKVILLE, MD, UNITED STATES, September 26, 2018 / EINPresswire.com/ -- [American Gene Technologies](#) announced today that its Chief Science Officer [C. David Pauza, Ph.D.](#) will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, California. Dr. Pauza's presentation will cover recent progress on [AGT's HIV cure](#) and gamma delta T cell immuno-oncology programs.

Organized by ARM and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The event's Partnering Forum on October 3-4 features more than 70 dedicated company presentations in addition to over 90 panelists and featured speakers.

The following are specific details regarding Dr. Pauza's presentation at the conference:

EVENT: 2018 Cell & Gene Meeting on the Mesa – Partnering Forum

DATE: October 3, 2018

TIME: 8:45pm

LOCATION: La Jolla Ballroom 2, Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: <http://www.meetingonthemesa.com/webcast> and will also be published on the conference



website shortly after the event.

Please visit www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at lparsons@alliancerm.org and interested media should contact Lyndsey Scull at lscull@alliancerm.org.

About Chief Science Officer C. David Pauza, Ph.D.:

C. David Pauza, Ph.D. is Chief Science Officer for American Gene Technologies and Professor of Medicine at the University of Maryland Medical School in Baltimore. Prior to joining AGT, Dr. Pauza was Associate Director for the university's prestigious Institute of Human Virology and Co-Leader of the Greenebaum Cancer Center Program in Viral Oncology. He is an internationally recognized expert in human virology and viral diseases including HIV, arenaviruses, poxviruses and herpesviruses. He has published more than 150 scientific papers and holds 6 US patents.

About American Gene Technologies (AGT):

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta ($\gamma\delta$) T cells to attack a variety of cancers. Four key patents in AGT's novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.

Website - <https://bit.ly/2PJPBXl>

LinkedIn - <https://www.linkedin.com/company/american-gene-technologies-international-inc/>

Twitter - @americangene, <https://twitter.com/americangene>

Facebook - @amerigene, <https://www.facebook.com/amerigene/>

Instagram - @americangenetechologies,
<https://www.instagram.com/americangenetechologies/>

American Gene Technologies Contacts:

C. Neil Lyons, Chief Financial Officer

Phone: (301) 337-2269

Email: info@americangene.com

Sasha Whitaker, Digital Marketing and Communications

Phone: (301) 337-2100

Email: swhitaker@americangene.com

American Gene Technologies

<https://www.americangene.com/>

(301) 337-2100

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.